Abstract：
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of liver disease worldwide. Endoscopic sleeve gastroplasty (ESG) has proven to be feasible, safe, and effective in the management of obesity. We performed the first systematic review and meta-analysis evaluating NAFLD and other metabolic parameters 12 months post-ESG. Four observational studies with a total of 175 patients were included. The results showed a significant (p < 0.05) reduction of 4.85 in hepatic steatosis index (95% CI - 6.02, - 3.67), 0.5 in NAFLD fibrosis score (95% CI - 0.80, - 0.19), 6.32 U/l in ALT (95% CI - 9.52, - 3.11), 17.28% in TWL (95% CI - 18.24, - 16.31), 6.31 kg/m2 in BMI (95% CI - 8.11, - 4.52), 47.97% in EWL (95% CI - 49.10, - 46.84), and 0.51% in HbA1c (95% CI - 0.90, - 0.12). ESG improves liver parameters, provides weight loss, and reduces HbA1c levels in patients suffering from NAFLD.
摘要：
非酒精性脂肪性肝病（NAFLD）是全球肝病的最常见原因。内镜套管胃成形术（ESG）已被证明是可行的，安全,并有效地管理肥胖。我们进行了首次系统评价和荟萃分析，评估了ESG后12个月的NAFLD和其他代谢参数。纳入四项观察性研究，共175例患者。结果显示肝脂肪变性指数显著(p<0.05)降低4.85(95%CI-6.02,-3.67),NAFLD纤维化评分为0.5（95%CI-0.80，-0.19），ALT为6.32U/l（95%CI-9.52，-3.11），TWL的17.28%（95%CI-18.24，-16.31），BMI为6.31kg/m2（95%CI-8.11，-4.52），EWL中的47.97%（95%CI-49.10，-46.84），HbA1c为0.51%（95%CI-0.90，-0.12）。ESG改善肝脏参数，提供减肥，并降低NAFLD患者的HbA1c水平。
